Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin

E. Giovannetti; P.A. Zucali; Y.G. Assaraf; L.G. Leon; K Smid; C. Alecci; F. Giancola; A. Destro; L. Gianoncelli; E. Lorenzi; M. Roncalli; A. Santoro; G.J. Peters

doi:https://doi.org/10.1038/bjc.2011.400

Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin

E. Giovannetti, P.A. Zucali, Y.G. Assaraf, L.G. Leon, K Smid, C. Alecci, F. Giancola, A. Destro, L. Gianoncelli, E. Lorenzi, M. Roncalli, A. Santoro, G.J. Peters

Medical oncology laboratory (VUmc)

Research output: Contribution to journal › Article › Academic › peer-review

43 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	1542-1553
Journal	British journal of cancer
Volume	105
Issue number	10
DOIs	https://doi.org/10.1038/bjc.2011.400
Publication status	Published - 2011

Access to Document

https://doi.org/10.1038/bjc.2011.400

https://research.vumc.nl/ws/files/877294/282702.pdf

Cite this

Giovannetti, E., Zucali, P. A., Assaraf, Y. G., Leon, L. G., Smid, K., Alecci, C., Giancola, F., Destro, A., Gianoncelli, L., Lorenzi, E., Roncalli, M., Santoro, A., & Peters, G. J. (2011). Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. British journal of cancer, 105(10), 1542-1553. https://doi.org/10.1038/bjc.2011.400

@article{4f5aa3ce88f742a7ab777e3d7c688ab4,

title = "Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin",

author = "E. Giovannetti and P.A. Zucali and Y.G. Assaraf and L.G. Leon and K Smid and C. Alecci and F. Giancola and A. Destro and L. Gianoncelli and E. Lorenzi and M. Roncalli and A. Santoro and G.J. Peters",

year = "2011",

doi = "https://doi.org/10.1038/bjc.2011.400",

language = "Undefined/Unknown",

volume = "105",

pages = "1542--1553",

journal = "British journal of cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "10",

}

Giovannetti, E, Zucali, PA, Assaraf, YG, Leon, LG, Smid, K, Alecci, C, Giancola, F, Destro, A, Gianoncelli, L, Lorenzi, E, Roncalli, M, Santoro, A & Peters, GJ 2011, 'Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin', British journal of cancer, vol. 105, no. 10, pp. 1542-1553. https://doi.org/10.1038/bjc.2011.400

Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. / Giovannetti, E.; Zucali, P.A.; Assaraf, Y.G. et al.
In: British journal of cancer, Vol. 105, No. 10, 2011, p. 1542-1553.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin

AU - Giovannetti, E.

AU - Zucali, P.A.

AU - Assaraf, Y.G.

AU - Leon, L.G.

AU - Smid, K

AU - Alecci, C.

AU - Giancola, F.

AU - Destro, A.

AU - Gianoncelli, L.

AU - Lorenzi, E.

AU - Roncalli, M.

AU - Santoro, A.

AU - Peters, G.J.

PY - 2011

Y1 - 2011

U2 - https://doi.org/10.1038/bjc.2011.400

DO - https://doi.org/10.1038/bjc.2011.400

M3 - Article

C2 - 21970874

SN - 0007-0920

VL - 105

SP - 1542

EP - 1553

JO - British journal of cancer

JF - British journal of cancer

IS - 10

ER -